Visit to Celregen in China
2023. 09. 22
Cellusion COO Joji Hayashida, CDO Nobuyuki Imai, and CMC Director Shinji Yoshizaki visited Celregen Therapeutics Ltd. (“Celregen”) in Shanghai, China. Celregen is a cell regenerative medic…
2023. 09. 22
Cellusion COO Joji Hayashida, CDO Nobuyuki Imai, and CMC Director Shinji Yoshizaki visited Celregen Therapeutics Ltd. (“Celregen”) in Shanghai, China. Celregen is a cell regenerative medic…
2023. 08. 24
Cellusion CEO, Dr. Hatou attended the award ceremony and made a presentation at the award winners’ pitch.He expressed gratitude to the supporting university and company, and also shared the prog…
2023. 07. 28
Cellusion CEO Shin Hatou, COO Joji Hayashida and CFO Takuya Kaneko visited Industrial Technology Research Institute (ITRI) in Taiwan. ITRI, established in 1973, is one of the foremost consortia in the…
2023. 06. 29
Pharmaceutical Technology, providing pharmaceutical trends, news & in-depth feature stories, published an article on the development of our lead program CLS001 (iPS cell-derived corneal endothelia…
2023. 06. 14
Cellusion CEO, Dr. Hatou gave a company presentation at the BIO International Convention 2023 in Boston, on the status of development, including the progress of its lead program CLS001, First-in-Human…
2023. 06. 14
Japan Innovation Night was a pitch event organized by JETRO & Japan Desk of CIC to bring together Japanese bio ventures in conjunction with the BIO International Conference 2023 in Boston. In addi…
2023. 04. 10
For more details, please see the following link.NHK WORLD-JAPAN News: Researchers announce first iPS cell transplant for cornea disease
2022. 08. 16
Hatou In 2015, I founded Cellusion. In the early stages of R&D, we were creating CECSi cells, corneal endothelial cell substitute from iPSC in the laboratory. Once the therapeutic effects wer…
2022. 08. 10
Our Reason for Supporting Cellusion Yamagishi KII’s mission statement is “Let us help your research, your invention, your innovation change the world.” As a venture capital, we aim to contr…